Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1653 - Retrospective study of paclitaxel in advanced therapy lines in the treatment of SCLC

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Cytotoxic Therapy

Tumour Site

Presenters

Damian von Eiff

Citation

Annals of Oncology (2018) 29 (suppl_8): viii596-viii602. 10.1093/annonc/mdy298

Authors

D. von Eiff1, F. Bozorgmehr1, P. Christopoulos1, I. Chung1, D. Bernhardt2, S. Rieken2, S. Liersch3, T. Muley4, S. Kobinger4, M. Thomas1, M. Steins1

Author affiliations

  • 1 Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), 69126 - Heidelberg/DE
  • 2 Department Of Radiation oncology, Heidelberg University Hospital; Heidelberg Institute of Radiation oncology (HIRO), Heidelberg, Germany, Heidelberg/DE
  • 3 Pharmacy Department, Thoraxklinik at Heidelberg University Hospital, Heidelberg/DE
  • 4 Translational Research Unit, Thoraxklinik at Heidelberg University Hospital; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), 69126 - Heidelberg/DE
More

Abstract 1653

Background

Extensive-disease small cell lung cancer (ED-SCLC) is usually first treated with etoposide-/platinum-based chemotherapy. Despite high initial response rates, progression occurs frequently. While topotecan is approved as 2nd-line therapy, further treatment is not standardized. One of the drugs administered in progressed SCLC is paclitaxel. Here, we retrospectively analyzed prognostic factors and outcome of paclitaxel-treated SCLC patients.

Methods

SCLC patients treated with paclitaxel between 2005 and 2015 at Thoraxklinik at Heidelberg University Hospital were retrospectively reviewed. Significant prognostic factors were identified by univariate (Kaplan-Meier) and multivariate (Cox-Regression) analysis.

Results

185 patients (119 men/66 women, median age 64 years, median ECOG performance status 1) were included. Paclitaxel was mainly given as 3rd- or 4th-line therapy (92%). The overall response rate was 17% and disease control rate (DCR) was 28%. Median progression-free survival (PFS) was 48 days (95%-CI: 42-54) and median overall survival (OS) 100 days (95%-CI: 84-116). Main toxicities were fatigue (25%) and peripheral neuropathy (17%), but no discontinuation of treatment was required. In 28%, the paclitaxel dose was reduced by 15-30%, mainly due to hematoxicities (in 57%). In univariate analysis, this was linked to a decrease in PFS (p = 0,05), while gender, age, performance status, number of metastatic sites, and presence of cerebral/hepatic metastases were not associated with changes in PFS. For OS, performance status, number of metastatic sites, cerebral/hepatic metastases, and dose reduction were significant (p < 0,05). In multivariate analysis, gender, age, and dose reduction retained as independent prognostic factors for PFS. In addition, performance status, cerebral/hepatic metastases, and pack years were identified as independent prognostic factors for OS.

Conclusions

With a DCR of 28% paclitaxel was still effective in heavily pretreated SCLC patients. However, patients should be selected carefully regarding age, performance status, and metastatic status. Especially, patients in good condition and without cerebral/hepatic metastases benefit from a paclitaxel therapy.

Clinical trial identification

Legal entity responsible for the study

Martin Steins.

Funding

Thoraxklinik at Heidelberg University Hospital.

Editorial Acknowledgement

Disclosure

F. Bozorgmehr: Honoraria: MSD, Novartis; Research funding: BMS. S. Rieken: Honoraria and travel expenses: Elekta Inc., Accuray Inc., AstraZeneca GmbH, Bristol-Myers Squibb, Lilly, Roche, DGP, DKG, Degro; IITs and other research funding: Bristol-Myers Squibb, Accuray Inc., Merck KGaA; Consulting or advisory role: Accuray Inc., AstraZeneca GmbH. S. Liersch: Honoraria: MSD, Sanofi; Advisory board: BMS, Amgen, MSD. T. Muley: Research grants: Roche, Chugai Pharma; Travel expenses, patent applications: Roche. M. Thomas: Honoraria: Lilly, BMS, MSD, Roche, Pfizer, AstraZeneca; Advisory boards: Lilly, BMS, MSD, Roche, Pfizer, AstraZeneca, Cellgene, Mediolanum. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.